Metropolitan Digital

Men's Weekly


.

Backlash against Johnson Johnson's COVID-19 vaccine is real and risky – here's how to make its rollout a success

  • Written by Tinglong Dai, Associate Professor of Operations Management & Business Analytics, Johns Hopkins Carey Business School, Johns Hopkins University School of Nursing
Backlash against Johnson Johnson's COVID-19 vaccine is real and risky – here's how to make its rollout a successThe concern is about more than one shot vs. two.Michael Ciaglo/Getty Images

More than 50 million Americans have received at least one dose of either the Pfizer or Moderna COVID-19 vaccine. So far, Americans have been largely brand-agnostic, but that’s about to change as a new vaccine rolls out.

The Johnson & Johnson vaccine has been hailed...

Read more: Backlash against Johnson Johnson's COVID-19 vaccine is real and risky – here's how to make its...

Metropolitan republishes selected articles from The Conversation USA with permission

Visit The Conversation to see more